Rafael Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (RFL) on August 4, 2025. The report discloses significant changes in executive leadership and related compensatory arrangements effective as of July 31, 2025, and August 4, 2025.
Key Financial Metrics and Compensation
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it details specific compensation and severance obligations:
- Joshua Fine (New COO): Base salary increased to $428,000 per annum; granted stock options valued at $25,000 on the grant date.
- N. Scott Fine (Vice Chairman/Ex-Officio Director): Severance payment of $852,168 to be paid in 36 semi-monthly installments; continued vesting of outstanding equity contingent on continued service.
- John Goldberg (Former CMO): Severance payment of $218,195; issuance of 99,429 shares of Class B common stock (vesting November 4, 2025) in lieu of a 2025 performance bonus; annual consulting fees of $100,000; accelerated vesting of all previously granted stock options and restricted stock.
Material Changes
The primary material changes involve the departure of the Chief Medical Officer and the appointment of a new Chief Operating Officer:
- Departure: John Goldberg resigned as Chief Medical Officer, effective July 31, 2025.
- Appointment: Joshua Fine was elected Chief Operating Officer on August 4, 2025. Mr. Fine previously served as CFO of CycloTherapeutics, LLC, a wholly owned subsidiary of the Company since March 2025.
- Related Party Transaction: Joshua Fine is the son of N. Scott Fine, who serves as an ex-officio director and Vice Chairman of the Board.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general business risks. The primary contingencies noted are the contractual obligations for severance payments and equity vesting outlined in the General Release Agreements and the Novation and Amendment to the Executive Employment Agreement.
Investor Verification Checklist
- Verify the full terms of the Novation and Amendment (Exhibit 10.1) regarding Joshua Fine's employment and equity grants.
- Review the General Release Agreement (Exhibit 10.2) for N. Scott Fine to confirm the conditions for continued equity vesting.
- Confirm the vesting schedule and valuation of the 99,429 shares issued to John Goldberg.
- Assess the impact of the CMO departure and COO appointment on the Company's clinical development pipeline, particularly given the subsidiary relationship with CycloTherapeutics.